Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction
P Calabresi, A Mechelli, G Natale… - Cell death & …, 2023 - nature.com
Although the discovery of the critical role of α-synuclein (α-syn) in the pathogenesis of
Parkinson's disease (PD) is now twenty-five years old, it still represents a milestone in PD …
Parkinson's disease (PD) is now twenty-five years old, it still represents a milestone in PD …
Genetics and pathogenesis of Parkinson's syndrome
Parkinson's disease (PD) is clinically, pathologically, and genetically heterogeneous,
resisting distillation to a single, cohesive disorder. Instead, each affected individual develops …
resisting distillation to a single, cohesive disorder. Instead, each affected individual develops …
Propagative α-synuclein seeds as serum biomarkers for synucleinopathies
Abnormal α-synuclein aggregation is a key pathological feature of a group of
neurodegenerative diseases known as synucleinopathies, which include Parkinson's …
neurodegenerative diseases known as synucleinopathies, which include Parkinson's …
Structures of α-synuclein filaments from human brains with Lewy pathology
Parkinson's disease (PD) is the most common movement disorder, with resting tremor,
rigidity, bradykinesia and postural instability being major symptoms. Neuropathologically, it …
rigidity, bradykinesia and postural instability being major symptoms. Neuropathologically, it …
Cognitive effects of Lewy body pathology in clinically unimpaired individuals
Abstract α-Synuclein aggregates constitute the pathology of Lewy body (LB) disease. Little is
known about the effects of LB pathology in preclinical (presymptomatic) individuals, either as …
known about the effects of LB pathology in preclinical (presymptomatic) individuals, either as …
Clinical effects of Lewy body pathology in cognitively impaired individuals
There is poor knowledge about the clinical effects of Lewy body (LB) pathology in patients
with cognitive impairment, especially when coexisting with Alzheimer's disease (AD) …
with cognitive impairment, especially when coexisting with Alzheimer's disease (AD) …
[HTML][HTML] Parkinson disease-associated cognitive impairment
Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …
Biomarkers for neurodegenerative diseases
Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …
the clinic but also to facilitate the development and monitoring of effective disease-modifying …
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
Summary In 2018, the US National Institute on Aging and the Alzheimer's Association
proposed a purely biological definition of Alzheimer's disease that relies on biomarkers …
proposed a purely biological definition of Alzheimer's disease that relies on biomarkers …
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic …
Background Plasma tau phosphorylated at threonine 217 (p-tau217) and plasma tau
phosphorylated at threonine 181 (p-tau181) are associated with Alzheimer's disease tau …
phosphorylated at threonine 181 (p-tau181) are associated with Alzheimer's disease tau …